Hutchmed Secures NMPA Approval for ATLED ICC

HUTCHMED announced conditional approval by China’s NMPA for ATLED® (fanregratinib) to treat adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements after prior systemic therapy. ATLED is an oral FGFR1/2/3 inhibitor, and the approval applies to FGFR2‑altered ICC in China, with Hutchmed retaining global rights to the therapy. ICC is an aggressive liver cancer with a 5‑year survival around 9%, and FGFR2 fusions occur in roughly 10–15% of ICC cases globally. The supporting Phase II/IIIb data reported an IRC‑assessed objective response rate of 42.5%, a rapid median time to response of about 1.4 months, and a median duration of response around 6.9 months, along with a high disease control rate. Hutchmed plans to rapidly deploy ATLED through its existing commercial network while continuing a confirmatory Phase IIIb trial to further validate efficacy and safety. The approvals position Hutchmed to address a meaningful unmet need in China’s oncology market and potentially strengthen its competitive standing in FGFR-driven cancers.